Y0001642
卡培他滨
European Pharmacopoeia (EP) Reference Standard
别名:
5′-脱氧-5-氟-N-[（戊氧基）羰基]胞苷, Ro-9-1978
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C15H22FN3O6
CAS Number:
分子量:
359.35
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
capecitabine
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C
InChI
1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
InChI key
GAGWJHPBXLXJQN-UORFTKCHSA-N
基因信息
human ... TYMS(7298)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Capecitabine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。 卡培他滨的激活遵循具有三个酶促步骤和两个中间代谢物5′-脱氧-5-氟胞苷（5′-DFCR）和5′-脱氧-5-氟尿苷（5′-DFUR）的途径，形成5-氟尿嘧啶。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
预防措施声明
危险分类
Carc. 1B - Muta. 2 - Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Nestor F Esnaola et al.
International journal of radiation oncology, biology, physics, 88(4), 837-844 (2014-03-13)
To evaluate, in a phase 2 study, the safety and efficacy of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer (BRPC or LAPC, respectively). Patients received gemcitabine
Valentina Sini et al.
Tumori, 99(6), 273e-277e (2014-02-08)
This report describes a case of ab initio metastatic HER2-positive breast cancer in a very young patient. The onset of breast cancer at such a young age is uncommon and could delay the diagnosis with unquestionable impact on the prognosis.
Takahiro Yamanashi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 41(1), 107-112 (2014-01-16)
A 77-year-old man who complained of melena was admitted to our department. Colonoscopy revealed a type 2 tumor in the hepatic flexure of the ascending colon. Biopsy examination revealed a poorly differentiated adenocarcinoma. Abdominal computed tomography(CT)revealed 3 tumors within the
Ferdinando Riccardi et al.
Tumori, 99(6), 257e-260e (2014-02-08)
Targeted therapies against HER2 (trastuzumab, lapatinib) have improved the efficacy of treatment and the outcome of patients with HER2-positive breast cancer. Lapatinib is a tyrosine kinase inhibitor targeting EGFR1 and HER2: it binds the intracellular domain of these receptors and
Moyuru Yamada et al.
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 111(3), 521-528 (2014-03-07)
A woman in her 60s was referred to our department with advanced rectal cancer and multiple unresectable metastases of the liver and peritoneum. She had been diagnosed with idiopathic thrombocytopenic purpura (ITP) in her 20s, with a platelet count maintained
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持